The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on April 27, 2026

Apr. 27, 2026

Strategic Advantages of Partnering with a Global High-Purity Heterocyclic Building Blocks Supplier: AiFChem

Indeterminate EIN Presswire

Apr. 27, 2026

MACOM to Enter into Agreements to Further Strengthen Supply Chain

Indeterminate GlobeNewswire

Apr. 27, 2026

Addgene Reinforces Its Expanding Role in Research with New Brand

Indeterminate GlobeNewswire

Apr. 27, 2026

SignNow Launches Docgen API to Automate Business Document Creation and Close the Gap Between Data and Signature

Indeterminate GlobeNewswire

Apr. 27, 2026

Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic

Indeterminate GlobeNewswire

Apr. 27, 2026

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

Indeterminate GlobeNewswire

Apr. 27, 2026

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Indeterminate GlobeNewswire

Apr. 27, 2026

Cerence to Announce Fiscal Second Quarter Results on May 7, 2026

Indeterminate GlobeNewswire

Apr. 27, 2026

Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

Indeterminate GlobeNewswire

Apr. 27, 2026

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Indeterminate GlobeNewswire

Apr. 27, 2026

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Indeterminate GlobeNewswire

Apr. 27, 2026

NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation

Indeterminate GlobeNewswire

Apr. 27, 2026

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Indeterminate GlobeNewswire

Apr. 27, 2026

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Indeterminate GlobeNewswire

Apr. 27, 2026

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Indeterminate GlobeNewswire

Apr. 27, 2026

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Indeterminate GlobeNewswire

Apr. 27, 2026

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

Indeterminate GlobeNewswire

Apr. 27, 2026

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Indeterminate GlobeNewswire

Apr. 27, 2026

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Indeterminate GlobeNewswire